Equities analysts expect that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce earnings of ($0.33) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Oxford Immunotec Global PLC’s earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.23). Oxford Immunotec Global PLC reported earnings per share of ($0.22) in the same quarter last year, which indicates a negative year-over-year growth rate of 50%. The business is scheduled to announce its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full year earnings of ($2.11) per share for the current year, with EPS estimates ranging from ($2.22) to ($2.00). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.25) to ($0.75). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Oxford Immunotec Global PLC.

A number of equities analysts have weighed in on the stock. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Cowen and Company reiterated a “buy” rating and set a $19.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. Piper Jaffray Companies reiterated a “buy” rating and set a $26.00 target price on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Robert W. Baird restated a “buy” rating and issued a $20.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Wednesday, November 1st. Finally, BTIG Research assumed coverage on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. They issued a “buy” rating and a $21.00 price objective for the company. Three research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $19.75.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) remained flat at $$13.11 during trading hours on Friday. The stock had a trading volume of 110,100 shares, compared to its average volume of 105,853. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global PLC has a twelve month low of $12.19 and a twelve month high of $19.51.

COPYRIGHT VIOLATION NOTICE: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/15/zacks-analysts-anticipate-oxford-immunotec-global-plc-oxfd-will-post-earnings-of-0-33-per-share.html.

In other Oxford Immunotec Global PLC news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $15.82, for a total transaction of $47,460.00. Following the completion of the sale, the director now directly owns 18,000 shares in the company, valued at $284,760. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Peter Wrighton-Smith sold 55,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total transaction of $922,900.00. The disclosure for this sale can be found here. Insiders sold 61,000 shares of company stock valued at $1,010,410 over the last 90 days. 8.11% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in OXFD. Perceptive Advisors LLC lifted its position in Oxford Immunotec Global PLC by 955.1% during the third quarter. Perceptive Advisors LLC now owns 465,356 shares of the company’s stock valued at $7,818,000 after purchasing an additional 421,250 shares during the last quarter. Alyeska Investment Group L.P. lifted its position in Oxford Immunotec Global PLC by 44.0% during the third quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock valued at $22,773,000 after purchasing an additional 413,904 shares during the last quarter. RTW Investments LP lifted its position in Oxford Immunotec Global PLC by 21.9% during the third quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock valued at $17,344,000 after purchasing an additional 185,453 shares during the last quarter. Renaissance Technologies LLC lifted its position in Oxford Immunotec Global PLC by 97.8% during the first quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock valued at $5,628,000 after purchasing an additional 179,600 shares during the last quarter. Finally, Stonepine Capital Management LLC bought a new stake in Oxford Immunotec Global PLC during the third quarter valued at approximately $2,726,000. Institutional investors and hedge funds own 78.79% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related stocks with our FREE daily email newsletter.